Pfizer will carry out a study in Toledo (PR) to assess the impact and

The city of Toledo, in western Paraná, will host an observational study that promises to understand the behavior of covid-19 in a “real life scenario in Brazil” after the completion of the vaccination program.

The study is a joint effort between pharmaceutical company Pfizer, Hospital Moinhos de Vento, the Federal University of Paraná (UFPR), the Health Department of Toledo and the National Immunization Program (PNI).

In a press conference, the researcher at Hospital Moinhos de Vento, Regis Goulart Rosa, analyzed that the large-scale study will be important to assess the effectiveness of the vaccine “in a real scenario” and prevent the most common variants in Brazil.

:: In Pernambuco, soccer games will have free mass testing points ::

“[O estudo permite] evaluate research questions that have not yet been answered, such as, for example: what impact of the vaccine on the occurrence of symptoms related to tiredness, fatigue, difficulty concentrating, sleeping; what is the duration of protection conferred by the doses recommended today by the national vaccination program”, explains the researcher.

People from 12 years old, with suspected symptoms of covid-19, who seek the public health service in the municipality can participate.

The study plans to recruit 4,500 people, who will be divided into two groups: follow-up cases (people who tested positive for covid-19) and control (people who had symptoms but tested negative).

:: Duque de Caxias, in RJ, suspends the obligation to wear masks in public places ::

Positive cases will be monitored by the team for one year. Recruitment should start within two to four weeks.

The Toledo campus of UFPR, together with the Biological Sciences sector of the university in Curitiba, will manage and analyze the positive samples.

“[O estudo dará] subsidies to weave more adequate strategies to control the pandemic. It will significantly contribute to the understanding of the pandemic,” said Cristina de Oliveira Rodrigues, Director of the Toledo Campus at UFPR.

pioneer study in the country

Toledo is the only Brazilian city to host this study. According to Julia Spinardi, Medical Leader of the Vaccine Area at Pfizer Brasil, the city was chosen based on a series of criteria, including geographic positioning, epidemiological control and excellence in the application of vaccines in the city.

:: Deputies of Paraná approve R$ 80 aid to families in situations of social vulnerability ::

Toledo has 142,645 inhabitants. Currently, 98.23% of the population over 12 years of age is vaccinated with at least the 1st dose of the vaccine. With two doses, they are about 54% of the population.

The researchers reinforced that the study does not foresee interference in the municipality’s vaccination plan. Initial study evaluations should be released within six to eight months of initiation, and final results should be released within 12 to 18 months of study initiation.

Source: BoF Paraná

Edition: Lia Bianchini

Deixe um comentário

O seu endereço de e-mail não será publicado. Campos obrigatórios são marcados com *